ReviewTherapeutic advances in chronic disease2016
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.
Review in Therapeutic advances in chronic disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Incidence of Glaucoma in Type 2 Diabetes Patients Treated With GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2025Pooled it
- Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool.Nutrients · 2023Pooled it
- Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022Pooled it
- GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives.Pharmaceutics · 2026Review
- Personalized Diabetes Therapy Part 2-Individual Diabetes Treatment (Standard of Care Plus, SOC+).Journal of personalized medicine · 2026Review
- The Anti-Inflammatory Role of GLP-1 RAs in Acute Lung Injury and Acute Respiratory Distress Syndrome.International journal of molecular sciences · 2026Review
- Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.Drug design, development and therapy · 2026Article
- Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records.EClinicalMedicine · 2026Article
- Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network.Cardiovascular diabetology · 2025Observational
- Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe ObesityJournal of clinical research in pediatric endocrinology · 2025Article
- Beyond lifestyle modification: the role of GLP-1 receptor agonists in treating pediatric obesity.Frontiers in pediatrics · 2025Review
- A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.Drug design, development and therapy · 2025Review
- Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence.Physiology & behavior · 2024Review
- Sex Differences in the Preventive Effect of Cardiovascular and Metabolic Therapeutics on Dementia.Biomolecules & therapeutics · 2023Review
- Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges.Cureus · 2023Review
- Regulation of Human Sortilin Alternative Splicing by Glucagon-like Peptide-1 (GLP1) in Adipocytes.International journal of molecular sciences · 2023Article
- A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.Life (Basel, Switzerland) · 2023Review
- Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway.CNS neuroscience & therapeutics · 2022Article
- Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.Advanced drug delivery reviews · 2021Review
- The deletion of glucagon-like peptide-1 receptors expressing neurons in the dorsomedial hypothalamic nucleus disrupts the diurnal feeding pattern and induces hyperphagia and obesity.Nutrition & metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a global obesity epidemic that will continue to be a financial burden on healthcare systems around the world. Tackling obesity through diet and exercise should always be the first intervention, but this has not proved to be effective for a large number of patients. Pharmacotherapeutic options have been limited and many previously available drugs have been withdrawn due to safety concerns. Currently, only bariatric surgery has the capability to induce both substantial and durable weight loss. This article briefly reviews the history of pharmacotherapy for obesity before focusing on the clinical trial evidence for the use of the GLP-1 agonist liraglutide as a weight loss agent and comparing its efficacy with other emerging drug therapies for obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.